Prognostic value of circulating calprotectin levels on the clinical course of COVID-19 differs between serum, heparin, EDTA and citrate sample types.
COVID-19
Calprotectin
Plasma
Pre-analytics
Prognostic value
Serum
Journal
Clinica chimica acta; international journal of clinical chemistry
ISSN: 1873-3492
Titre abrégé: Clin Chim Acta
Pays: Netherlands
ID NLM: 1302422
Informations de publication
Date de publication:
15 Jan 2022
15 Jan 2022
Historique:
received:
15
11
2021
revised:
07
12
2021
accepted:
09
12
2021
pubmed:
18
12
2021
medline:
12
1
2022
entrez:
17
12
2021
Statut:
ppublish
Résumé
During the recent SARS-CoV-2 pandemic, circulating calprotectin (cCLP) gained interest as biomarker to predict the severity of COVID-19. We aimed to investigate the prognostic value of cCLP measured in serum, heparin, EDTA and citrate plasma. COVID-19 patients were prospectively included, in parallel with two SARS-CoV-2 negative control populations. The prognostic value of cCLP was compared with IL-6, CRP, LDH, procalcitonin, and the 4C-mortality score by AUROC analysis. For the 136 COVID-19 patients, cCLP levels were higher compared to the respective control populations, with significantly higher cCLP levels in serum and heparin than in EDTA or citrate. Higher cCLP levels were obtained for COVID-19 patients with i) severe/critical illness (n = 70), ii) ICU admission (n = 66) and iii) need for mechanical ventilation/ECMO (n = 25), but iv) not in patients who deceased within 30 days (n = 41). The highest discriminatory power (AUC [95% CI]) for each defined outcome was i) CRP (0.835 [0.755-0.914]); ii) EDTA cCLP (0.780 [0.688-0.873]); iii) EDTA cCLP (0.842 [0.758-0.925]) and iv) the 4C-mortality score (0.713 [0.608-0.818]). Measuring cCLP in COVID-19 patients helps the clinician to predict the clinical course of COVID-19. The discriminatory power of EDTA and citrate plasma cCLP levels often outperforms heparin plasma cCLP levels.
Identifiants
pubmed: 34919937
pii: S0009-8981(21)00433-2
doi: 10.1016/j.cca.2021.12.011
pmc: PMC8669946
pii:
doi:
Substances chimiques
Citrates
0
Leukocyte L1 Antigen Complex
0
Citric Acid
2968PHW8QP
Heparin
9005-49-6
Edetic Acid
9G34HU7RV0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
54-61Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Références
Int J Mol Sci. 2021 Feb 08;22(4):
pubmed: 33567747
N Engl J Med. 2021 Jul 8;385(2):179-186
pubmed: 34161052
Exp Biol Med (Maywood). 2017 Apr;242(8):859-873
pubmed: 27895095
Cell Mol Immunol. 2020 Sep;17(9):992-994
pubmed: 32620787
Sci Rep. 2021 Aug 10;11(1):16212
pubmed: 34376762
Reumatologia. 2016;54(6):306-309
pubmed: 28115781
Scand J Clin Lab Invest. 2018 Feb - Apr;78(1-2):102-108
pubmed: 29278951
Int J Mol Sci. 2021 Jul 12;22(14):
pubmed: 34299080
J Clin Med. 2021 Feb 15;10(4):
pubmed: 33672040
Gut. 2019 Dec;68(Suppl 3):s1-s106
pubmed: 31562236
Scand J Clin Lab Invest. 1990 Dec;50(8):837-41
pubmed: 2128131
Clin Chem Lab Med. 2019 Dec 18;58(1):40-49
pubmed: 31665107
Gut. 2021 Oct;70(10):1978-1988
pubmed: 34145045
J Infect. 2021 Apr;82(4):84-123
pubmed: 33217473
J Appl Lab Med. 2018 May 1;2(6):851-856
pubmed: 33636827
Clin Chim Acta. 2021 Jun;517:149-155
pubmed: 33689693
J Exp Med. 2020 Dec 7;217(12):
pubmed: 32926097
J Infect. 2021 Feb;82(2):e40-e42
pubmed: 32795482
Clin Chem Lab Med. 2021 Feb 23;59(8):e317-e321
pubmed: 33641273
J Transl Int Med. 2019 Dec 31;7(4):126-131
pubmed: 32010597
BMJ. 2020 Apr 7;369:m1328
pubmed: 32265220
Expert Rev Clin Immunol. 2021 May;17(5):431-443
pubmed: 33750254
J Leukoc Biol. 2021 Jan;109(1):67-72
pubmed: 32869342
Scand J Gastroenterol. 2019 Oct;54(10):1214-1219
pubmed: 31526273
Cell. 2020 Sep 17;182(6):1401-1418.e18
pubmed: 32810439
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
Clin Chem Lab Med. 2021 Nov 01;60(2):e57-e60
pubmed: 34714981
Ir J Med Sci. 2022 Feb;191(1):59-64
pubmed: 33641087
Healthcare (Basel). 2021 Jul 29;9(8):
pubmed: 34442092
BMJ. 2020 Sep 9;370:m3339
pubmed: 32907855
Int J Mol Med. 2017 Jul;40(1):31-38
pubmed: 28498464